Journal of geriatric oncology · 2025
Personalized risk assessment of frailty in long-term cancer survivors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Forman Rebecca, Westvold Sarah J, Long Jessica B, Fan Jane, Hyslop Terry, Conlin Kerry, Jacobson Sofia, Wang Shi-Yi, Leapman Michael S, Cecchini Michael, Leeds Ira, Spees Lisa, Presley Carolyn, Yasin Faiza, Taylor Melissa, Kwaramba Tendai, Gross Cary P, Oeffinger Kevin, Dinan Michaela A
Аннотация
INTRODUCTION: Due to the growth of the cancer survivor population, strategies to facilitate efficient delivery of survivorship care are critical to reduce the risk of adverse events associated with frailty. The objective of this study was to develop a risk stratification tool to identify long-term survivors at the highest risk of becoming frail 5-10 years after cancer diagnosis.
MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) dataset linked with Medicare data to identify patients with stage I-III breast, prostate, colon, or rectal cancers who lived at least five years from diagnosis and were not severely frail at year five post-diagnosis. Frailty was assessed using the claims-based Kim Frailty Index (FI) categorized by recommended thresholds. Restricted mean survival time (RMST) regression was used to identify clinical and demographic characteristics associated with frailty progression, defined as an increased category of the FI. Significant predictors were used to create clinical prediction rules and stratify survivors into low, intermediate, and high-risk groups.
RESULTS: A total of 87,229 five-year survivors were included. At five years from diagnosis (time zero), 22 % of patients not frail at cancer diagnosis had new onset frailty and were mildly or moderately frail; at 10 years from diagnosis, 61 % had developed new or worsening frailty. Advanced age, comorbidities (RMST ratios ranging from 0.67 [95 % CI 0.65-0.70] to 0.80 [95 % CI 0.77-0.84], baseline moderate frailty at cancer diagnosis (RMST ratios ranging from 0.79 [95 % CI 0.76-0.83] to 0.86 [95 % CI 0.83-0.90]) and at five years post-diagnosis (RMST ratios ranging from 0.63 [95 % CI 0.62-0.64] to 0.71 [95 % CI 0.69-0.73]), living in a high poverty area (RMST ratios ranging from 0.91 [95 % CI 0.87-0.94] to 0.96, [95 % CI 0.93-0.99], and systemic treatments four to five years post-diagnosis (RMST ratios ranging from 0.77 [95 % CI: 0.70-0.84] to 0.86, [95 % CI: 0.84-0.89] were associated with less average time without frailty.
DISCUSSION: Age, comorbidities, prior frailty, and late treatment were associated with frailty in older breast, prostate, colon, and rectal cancer survivors. This risk stratification model can be used by clinicians to assess cancer and age-related risk of frailty and facilitate timely intervention.
MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) dataset linked with Medicare data to identify patients with stage I-III breast, prostate, colon, or rectal cancers who lived at least five years from diagnosis and were not severely frail at year five post-diagnosis. Frailty was assessed using the claims-based Kim Frailty Index (FI) categorized by recommended thresholds. Restricted mean survival time (RMST) regression was used to identify clinical and demographic characteristics associated with frailty progression, defined as an increased category of the FI. Significant predictors were used to create clinical prediction rules and stratify survivors into low, intermediate, and high-risk groups.
RESULTS: A total of 87,229 five-year survivors were included. At five years from diagnosis (time zero), 22 % of patients not frail at cancer diagnosis had new onset frailty and were mildly or moderately frail; at 10 years from diagnosis, 61 % had developed new or worsening frailty. Advanced age, comorbidities (RMST ratios ranging from 0.67 [95 % CI 0.65-0.70] to 0.80 [95 % CI 0.77-0.84], baseline moderate frailty at cancer diagnosis (RMST ratios ranging from 0.79 [95 % CI 0.76-0.83] to 0.86 [95 % CI 0.83-0.90]) and at five years post-diagnosis (RMST ratios ranging from 0.63 [95 % CI 0.62-0.64] to 0.71 [95 % CI 0.69-0.73]), living in a high poverty area (RMST ratios ranging from 0.91 [95 % CI 0.87-0.94] to 0.96, [95 % CI 0.93-0.99], and systemic treatments four to five years post-diagnosis (RMST ratios ranging from 0.77 [95 % CI: 0.70-0.84] to 0.86, [95 % CI: 0.84-0.89] were associated with less average time without frailty.
DISCUSSION: Age, comorbidities, prior frailty, and late treatment were associated with frailty in older breast, prostate, colon, and rectal cancer survivors. This risk stratification model can be used by clinicians to assess cancer and age-related risk of frailty and facilitate timely intervention.